Transmission relay system
By employing synthetic transcription factors with selective binding sites, the method addresses issues of high background signaling and variation in cellular signaling pathway studies, improving the signal-to-noise ratio and accuracy of screening for cellular signaling pathway activators and inhibitors.
Patent Information
- Application Number
- KR1020217042717
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-28
- Filing Date
- 2020-05-27
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2040-05-27
AI Technical Summary
Existing methods for investigating cellular signaling pathways suffer from high background signaling, high coefficients of variation, and low signal-to-noise ratios due to the 'leakage' nature of endogenous response factor binding promoters and low absolute values of reporter activation.
The use of non-endogenous synthetic transcription factors that are highly selective for synthetic transcription factor binding sites, reducing background signaling and increasing the signal-to-noise ratio by incorporating a transcription factor nucleic acid with a reaction factor regulatory promoter and a reporter nucleic acid, each with specific nucleotide sequences, and optionally including a unique molecular identifier (UMI) for multiplexing.
This approach reduces biological variation, enhances signal-to-noise ratio, and allows for more accurate screening of small molecules and biological agents by minimizing background signal and increasing the specificity of reporter activation.
Smart Images

Figure 112021150894532-PCT00014_ABST
Abstract
Description
Technology Field
[0001] Cross-reference
[0002] This application claims priority to U.S. Provisional Application No. 62 / 853,637 filed on May 28, 2019, the full text of which is incorporated herein by reference.
[0003] The present invention describes nucleic acids, systems, and methods useful for investigating cellular signaling pathway responses, screening antagonists or agonists of cellular signaling pathways, or discovering novel cellular signaling pathways. Methods previously known in the art utilize endogenous response factor regulatory promoters located near nucleic acids encoding reporter molecules. These methods suffer from high levels of background signaling of the reporter molecule due to the "leakage" nature of endogenous response factor binding promoters in cells. Additionally, these methods suffer from high coefficients of variation. Finally, these methods suffer from low absolute values of reporter activation, resulting in a low signal-to-noise ratio. The nucleic acids and systems of the present disclosure reduce levels of biological variation, increase the signal-to-noise ratio of the reporter signal, and reduce background signaling by using non-endogenous synthetic transcription factors that are highly selective for synthetic transcription factor binding sites. Therefore, since the transcription of the reporter molecule is not initiated by endogenous transcription factors, it helps to reduce the background signal of the reporter molecule and increase the signal-to-noise ratio. Such nucleic acids and systems are useful for screening small molecules of signaling pathways, such as G-protein coupled receptors, receptor tyrosine kinases, ion channels, and nuclear receptors, or biological agents or antagonists. In a broad sense, the system comprises a) a response element regulatory promoter located near the 5' end of a synthetic transcription factor reading frame; and b) a nucleic acid encoding a promoter element that can be coupled by a synthetic transcription factor, wherein the promoter element is located near the 5' end of a reporter gene reading frame. In the present system, the reporter gene may include a unique molecular identifier (UMI) that allows for multiplexing of the reporter assay.
[0004] In one aspect, the present invention describes a transcription relay system comprising: a transcription factor nucleic acid comprising a nucleotide sequence of a reaction factor regulatory promoter and a nucleotide sequence encoding a synthetic transcription factor, wherein the reaction factor regulatory promoter nucleotide sequence is located at the 5' position relative to the nucleotide sequence encoding the synthetic transcription factor; and a reporter nucleic acid comprising a nucleotide sequence of a synthetic transcription factor promoter and a nucleotide sequence encoding a reporter, wherein the synthetic transcription factor promoter nucleotide sequence is located at the 5' position relative to the nucleotide sequence encoding the reporter, and the synthetic transcription factor promoter nucleotide sequence is capable of being bound by the synthetic transcription factor. In certain embodiments, the reaction factor regulatory promoter nucleotide sequence comprises a cAMP reaction factor nucleotide sequence, an NFAT transcription factor reaction factor nucleotide sequence, an FOS promoter nucleotide sequence, or a serum reaction factor nucleotide sequence. In certain embodiments, the synthetic transcription factor comprises a DNA binding domain from a first transcription factor and a transcription activation domain from a second transcription factor. In certain embodiments, the DNA binding domain is from Gal4, PPR1, Lac9, or LexA. In certain embodiments, the DNA binding domain comprises an amino acid sequence that is at least about 90% identical to that described in SEQ ID NO. 1. In certain embodiments, the DNA binding domain comprises an amino acid sequence that is at least about 95% identical to that described in SEQ ID NO. 1. In certain embodiments, the DNA binding domain comprises the amino acid sequence described in SEQ ID NO. 1. In certain embodiments, the DNA binding domain comprises an amino acid sequence variant of SEQ ID NO. 1. In certain embodiments, the transcription activation domain comprises VP64, p65, and Rta.In a specific embodiment, the transcription activation domain comprises an amino acid sequence that is at least about 90% identical to that described in SEQ ID NO. 14. In a specific embodiment, the transcription activation domain comprises an amino acid sequence that is at least about 95% identical to that described in SEQ ID NO. 14. In a specific embodiment, the transcription activation domain comprises the amino acid sequence described in SEQ ID NO. 14. In a specific embodiment, the transcription activation domain comprises an amino acid sequence variant of SEQ ID NO. 14, said sequence variant increases or decreases transcriptional activation. In a specific embodiment, the synthetic transcription factor comprises an amino acid sequence variant described in SEQ ID NO. 10. In a specific embodiment, the synthetic transcription factor comprises a polypeptide sequence that destabilizes the synthetic transcription factor. In a specific embodiment, the polypeptide sequence that destabilizes the synthetic transcription factor comprises a PEST or CL1 polypeptide sequence. In a specific embodiment, the synthetic transcription factor promoter nucleotide sequence comprises a nucleotide sequence that can be bound by Gal4, PPR1, Lac9, or LexA. In certain embodiments, the reporter comprises a fluorescent protein, a luciferase protein, a beta-galactosidase, a beta-glucuronidase, a chloramphenicol acetyltransferase, a secreted placental alkaline phosphatase, or a unique molecular identifier. In certain embodiments, the reporter comprises a fluorescent protein, a luciferase protein, a beta-galactosidase, a beta-glucuronidase, a chloramphenicol acetyltransferase, or a secreted placental alkaline phosphatase, and a UMI. In certain embodiments, the unique molecular identifier is unique to the test polypeptide, and the test polypeptide is encoded by the reporter nucleic acid. In certain embodiments, the transcription factor nucleic acid comprises a nucleotide sequence adjacent to the reaction factor regulatory promoter nucleotide sequence that can be bound by a transcription repressor.In certain embodiments, the transcription factor nucleic acid comprises a nucleotide sequence adjacent to the response factor regulatory promoter nucleotide sequence that extends the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor. In certain embodiments, the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor comprises one or more sequences that reduce the translation of the synthetic transcription factor. In certain embodiments, the transcription factor nucleic acid and the reporter nucleic acid are components of a single nucleic acid. In certain embodiments, a cell comprising the relay system is described as described herein. In certain embodiments, the cell comprises a eukaryotic cell. In certain embodiments, the cell comprises a mammalian cell. In certain embodiments, the transcription factor nucleic acid, the reporter nucleic acid, or both the transcription factor nucleic acid and the reporter nucleic acid are incorporated into the genome of the cell as a single copy. In certain embodiments, a cell population comprising the relay system is described as described herein. In certain embodiments, the cell population comprises a eukaryotic cell population. In certain embodiments, the cell population comprises a mammalian cell population. In certain embodiments, the cell or cell population comprises high basal reporter activity. In certain embodiments, the cell or cell population comprises high basal reporter activity that is at least about 30x greater than the background, where the background is the level of reporter activity observed for a parent cell or parent cell line that does not contain a reporter. In certain embodiments, the cell or cell population comprises a low coefficient of biological variation for reporter activity. In certain embodiments, the cell or cell population comprises a low coefficient of biological variation for reporter activity that is less than about 0.5.
[0005] In certain embodiments, as described herein, a method for testing the effect of a test agent on the activity of a reaction element regulatory promoter is described, comprising the step of contacting a cell or a population of cells with said test substance. In certain embodiments, said test agent is a chemical substance. Brief explanation of the drawing
[0006] Fig. 1a This shows a schematic diagram of a transcription relay system, illustrating the transcription factor nucleic acid (left) and the reporter nucleic acid (right). Fig. 1b This illustrates a nucleic acid sequence encoding a reporter containing a unique RNA sequence. Fig. 2 This shows the reporter yield for cells possessing a single integrated CRE-luciferase (gray) and cells possessing a single integrated UAS-luciferase with multiple copies of semi-randomly integrated CRE-Gal4-VPR (black). Fig. 3 It was executed triple-layered, Fig. 2 It shows the coefficient of variation for each sample shown in. Fig. 4 This shows the effect of a destabilization sequence tag (degron tag) on the Gal4-VPR promoter nucleotide sequence on the induced pluripotency of the transcription relay system. Fig. 5 This shows a cell library generated from NFAT-relay isoclonal cell lines. The cell lines were screened for their ability to detect NFAT-relay reporter activity against Gq-coupled GPCRs using positive control compounds. Receptor-compound combinations that generated a signal with a false discovery rate (FDR) of less than 0.001 or a max_Q greater than 3 were considered significant hits. Libraries cb29 and cb37 generated the most significant hits in this screen. Fig. 6This shows the coefficient of variation (variance) of the basal activity of the isoclonal cell line used to generate the cell library. Specific details for implementing the invention
[0007] In one aspect, the present invention describes a transcription relay system comprising: (a) a transcription factor nucleic acid comprising a nucleotide sequence of a reaction factor regulator promoter and a nucleotide sequence encoding a synthetic transcription factor, wherein the reaction factor regulator promoter nucleotide sequence is located at the 5' position relative to the nucleotide sequence encoding the synthetic transcription factor; and (b) a reporter nucleic acid comprising a nucleotide sequence of a synthetic transcription factor promoter and a nucleotide sequence encoding a reporter, wherein the synthetic transcription factor promoter nucleotide sequence is located at the 5' position relative to the nucleotide sequence encoding the reporter, and the synthetic transcription factor promoter nucleotide sequence is capable of being bound by the synthetic transcription factor.
[0008] In another aspect, the present invention describes a method for testing the effect of a test substance on the activity of a reaction factor regulatory promoter, comprising: (a) a step of contacting a cell with the test substance, wherein the cell comprises: (i) a transcription factor nucleic acid comprising a nucleotide sequence of a reaction factor regulatory promoter and a nucleotide sequence encoding a synthetic transcription factor, wherein the nucleotide sequence of the reaction factor regulatory promoter is located at the 5' position relative to the nucleotide sequence encoding the synthetic transcription factor; and (ii) a reporter nucleic acid comprising a nucleotide sequence of a synthetic transcription factor promoter and a nucleotide sequence encoding a reporter, wherein the nucleotide sequence of the synthetic transcription factor promoter is located at the 5' position relative to the nucleotide sequence encoding the reporter, and the nucleotide sequence of the synthetic transcription factor promoter is capable of being bound by the synthetic transcription factor; and (b) a step of performing at least one assay to measure the transcription of the reporter.
[0009] In the following description, specific specific details are provided to provide a complete understanding of the various embodiments. However, those skilled in the art will understand that the provided embodiments may be practiced without these details. Unless otherwise required by the context, the word “comprise” and variations thereof, such as “comprises” and “comprises,” throughout the specification and the claims below, should be interpreted in an open-ended, inclusive sense, i.e., “comprises, but not limited thereto.” As used in this specification and the appended claims, the singular forms “one” (“a,” “an”) and “it” include multiple referents unless the context clearly indicates otherwise. Also, note that the term “or” is generally used to include “and / or” unless the context clearly indicates otherwise. Additionally, headings provided herein are for convenience only and do not describe the scope or meaning of the claimed embodiments.
[0010] As used in this institution, the term "about" refers to an amount close to 10% of the mentioned amount.
[0011] The terms "polypeptide" and "protein" are used interchangeably and refer to polymers of amino acid residues, not limited to the minimum length. The provided polypeptide chain and other peptides, including linker and binding peptides, may contain amino acid residues including natural and / or non-natural amino acid residues. The terms also include post-expression modifications of the polypeptide, e.g., glycosylation, sialation, acetylation, phosphorylation, etc. In some aspects, the polypeptide may include modifications relative to the original or natural sequence, provided that the protein maintains the desired activity. These modifications may be intentional, such as by using a positional mutagenic method, or accidental, such as through errors resulting from PCR amplification or mutations in the host producing the protein.
[0012] Sequence identity (%) relative to a reference polypeptide sequence is the percentage (%) of amino acid residues in a candidate sequence that are identical to amino acid residues in a reference polypeptide sequence, after aligning the sequences and, if necessary, introducing gaps to achieve maximum sequence identity (%), and without considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining amino acid sequence identity (%) can be achieved in various known ways, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Suitable parameters for aligning the sequences can be determined, including algorithms necessary to achieve maximum alignment over the entire length of the sequences to be compared. However, for the purposes herein, amino acid sequence identity (%) values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program is authored by Genentech, Inc., and its source code has been submitted to the U.S. Copyright Office (U.S., Washington, D.C. 20559) along with user manuals and is registered under U.S. Copyright No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. (South San Francisco, California, USA) or can be compiled from the source code. The ALIGN-2 program must be compiled for use on UNIX operating systems, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and are not changed.
[0013] In situations where ALIGN-2 is used for amino acid sequence comparison, the amino acid sequence identity (%) of a given amino acid sequence A with respect to B, or with respect to B (or alternatively, it may be expressed as a given amino acid sequence A having or containing a specific amino acid sequence identity (%) with respect to B, or with respect to B) is calculated as follows: 100 x fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in the alignment of A and B in the ALIGN-2 program, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not the same as the length of amino acid sequence B, the amino acid sequence identity (%) of A with respect to B is not the same as the amino acid sequence identity (%) of B with respect to A. Unless specifically stated otherwise, all amino acid sequence identity (%) values used herein may be obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0014] When used herein to describe a nucleic acid sequence relative to a reference sequence, the terms “identity,” “identical,” or “% identical” may be determined using a formula as described in the literature [Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87: 2264-2268, 1990, modified as in Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993)]. The said formula is introduced into the basic local alignment search tool (BLAST) program of the literature [Altschul et al. (J. Mol. Biol. 215: 403-410, 1990)]. Sequence identity (%) may be determined using the most recent version of BLAST as of the filing date of this application.
[0015] The polypeptide of the system described herein may be encoded by a nucleic acid. A nucleic acid is a type of polynucleotide comprising two or more nucleotide bases. In certain embodiments, the nucleic acid is a component of a vector that can be used to deliver the polypeptide-coding polynucleotide into a cell. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a genome-integrated vector, or "integration vector," which can be integrated into the chromosomal DNA of a host cell. Another type of vector is an "episomal" vector, e.g., a nucleic acid capable of extrachromosomal replication. A vector capable of directing the expression of an operatively linked gene is referred herein to as an "expression vector." Suitable vectors include plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, viral vectors, etc. In an expression vector, regulatory elements, e.g., promoters, enhancers, and polyadenylation signals for use in transcriptional control, may be derived from mammalian, microbial, viral, or insect genes. Generally, the ability to replicate within a host and selection genes that facilitate recognition of the transformant, which are conferred by the replication origin, may be additionally introduced. Vectors derived from viruses, such as lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses, may be used. Plasmid vectors may be linearized for integration into chromosomal locations. The vector may contain sequences that direct site-specific integration to a defined location in the genome or a restricted set of regions (e.g., AttP-AttB recombination). Additionally, the vector may contain sequences derived from transposable factors for integration.
[0016] As used herein, the terms “transfection” or “transfected” refer to a method of intentionally introducing exogenous nucleic acids into cells through processes commonly used in the laboratory. Transfection may be performed, for example, by lipofection, calcium phosphate precipitation, viral transduction, or electroporation. Transfection may be transient or stable.
[0017] As used herein, the term "transfection efficiency" refers to the size or extent to which a cell population contains exogenous nucleic acids. Transfection efficiency may be measured as the percentage (%) of cells in a given population into which exogenous nucleic acids have been introduced, relative to the total cell population within the system. Transfection efficiency may be measured in both transiently and stably transfected cells.
[0018] As used herein, the term "biologically active polypeptide" refers to a polypeptide expressed by a cell that regulates gene expression. Biologically active polypeptides may regulate gene expression directly, in response to a stimulus, through signal transduction via one or more intermediate molecules or polypeptides, or through any other mechanism. Biologically active polypeptides may be transmembrane polypeptides (e.g., receptor or channel proteins), intracellular polypeptides (e.g., signal transduction intermediates), extracellular polypeptides, or secreted polypeptides.
[0019] As used herein, "reporter activity" refers to experimental readings from a reporter. For example, a luciferase reporter yields a luminescence reading when cultured with an appropriate substrate. Other reporters, such as fluorescent proteins, may not require a substrate but can be measured, for example, by microscopy or a fluorescent plate reader.
[0020] System Overview
[0021] The systems, nucleic acids, and methods described herein are useful for screening the presence and / or activation levels of response element binding promoters. The nucleic acids, systems, and methods described herein can activate transcription with a lower level of background signal than traditional reporter systems. In certain embodiments, the response element binding promoter is activated at the end of a cell signaling cascade. In certain embodiments, the presence of the response element binding promoter may be measured before and after an external stimulus, such as a physical or chemical stimulus, or compared with a control condition running in parallel. The chemical stimulus may be an agonist or antagonist small molecule or biological molecule. In certain embodiments, the system is useful for screening for drug discovery purposes. The system comprises nucleic acid(s) comprising at least a response element regulatory promoter, a synthetic transcription factor promoter, a synthetic transcription factor, and a reporter. The response element regulatory promoter is located at the 5' for the synthetic transcription factor and activates the transcription of the synthetic transcription factor when the response element binding promoter is present. Subsequently, upon translation, the synthetic transcription factor may bind to a synthetic transcription factor promoter located at the 5' position relative to the nucleic acid sequence encoding the reporter. While bound, the synthetic transcription factor promoter activates the transcription of the nucleic acid sequence encoding the reporter. In certain embodiments, the reporter is a polypeptide. In certain embodiments, the reporter is a UMI. An additional optional feature of the system includes a nucleotide sequence adjacent to a reaction element regulatory promoter nucleotide sequence that may be bound by a transcription repressor. In certain embodiments, the nucleotide sequence adjacent to the reaction element regulatory promoter nucleotide sequence extends the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor. In certain embodiments, the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor has one or more sequences that reduce the translation of the synthetic transcription factor.
[0022] One non-limiting embodiment of the present invention is Fig. 1a It is presented in. Transcription factor nucleic acid ( 100 ) is presented on the left. Transcription factor nucleic acid ( 100 ) contains nucleotide sequences encoding synthetic transcription factors ( 104 Reaction factor regulatory promoter nucleic acid at the 5' position of ) 102 ) exists. On the right is the nucleotide sequence encoding the reporter ( 114 The synthetic transcription factor promoter nucleotide sequence located at the 5' of ) 112 Reporter nucleic acid containing ) 110 ...is present. In certain embodiments, the transcription factor nucleic acid and the reporter nucleic acid exist in separate nucleic acid molecules, for example, separate plasmids or viral vectors. In certain embodiments, the transcription factor nucleic acid and the reporter nucleic acid are linear. In certain embodiments, the transcription factor nucleic acid and the reporter nucleic acid exist on the same nucleic acid, which may be a plasmid, a viral vector, a linear, or any other configuration.
[0023] A non-limiting embodiment of a nucleotide sequence encoding a reporter Fig. 1b It is presented in. The nucleotide sequence encoding the reporter ( 114 ) is a nucleic acid sequence encoding a reporter polypeptide ( 122 In addition to ) the nucleic acid sequence encoding UMI ( 124 Includes ). Sequence( 124 ) is also known as a Unique Molecular Identifier (UMI). UMI is UMI is ( 102Specific biologically active polypeptides that result in the activation of the response element regulatory promoter nucleic acid can be identified. As a non-limiting example, biologically active polypeptides may include specific G-coupled protein receptors, of which hundreds are known. Therefore, signal transduction of several different biologically active polypeptides can be easily and rapidly investigated in multiple formats via the UMI element. Additionally, the relay system reduces background signal transduction through the response element regulatory promoter. This allows for more accurate quantification and reduces the number of false-positive test compounds in any multiple screening for compounds capable of activating biologically active polypeptides. In certain embodiments, the nucleic acid sequence encoding the reporter polypeptide does not exist. In certain embodiments, the nucleic acid sequence encoding the UMI does not exist. In certain embodiments, the nucleic acid sequence encoding the UMI is located at the 5' of the nucleic acid sequence encoding the reporter polypeptide. In certain embodiments, the nucleic acid sequence encoding the reporter polypeptide is located at the 5' of the nucleic acid sequence encoding the UMI.
[0024] In certain embodiments, the nucleic acid encoding the reporter codes for a reporter polypeptide. In certain embodiments, the reporter polypeptide can be detected directly. In certain embodiments, the reporter polypeptide generates a detectable signal regarding the enzymatic activity of the protein toward the substrate. In certain embodiments, detection of the reporter polypeptide can be achieved quantitatively. In certain embodiments, the reporter polypeptide comprises a luciferase protein, beta-galactosidase, beta-glucuronidase, chloramphenicol acetyltransferase, secreted placental alkaline phosphatase, or a combination thereof. In certain embodiments where the reporter polypeptide is a luciferase protein, non-limiting examples of substrates include firefly luciferin, Latia luciferin, bacterial luciferin, coelenterazine, dinoflagellate luciferin, barguline, and 3-hydroxyhispidine.
[0025] In a specific embodiment, the nucleic acid encoding the reporter codes for a UMI. The UMI comprises a short sequence of nucleotides unique to the nucleic acid. The UMI may have a length of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleotides. The UMI may be detected by any suitable method that enables sequence determination of the UMI, such as a next-generation sequencing method. The method for detecting the UMI may be quantitative and includes a next-generation sequencing method.
[0026] In certain embodiments, the present invention describes a method for efficiently utilizing a system comprising a transcription factor nucleic acid and a reporter nucleic acid encoding nucleic acid for use in drug discovery. In certain embodiments, the present method comprises the steps of: contacting the nucleic acid(s) with a cell or a population of cells under conditions sufficient for the nucleic acid(s) to be internalized and developed (e.g., transfection) by the cell; contacting the cell with a physical or chemical stimulus; and measuring the activation of the reporter element by one or more assays. In certain embodiments, the present method comprises the steps of: contacting a cell or a population of cells comprising the transcription factor nucleic acid and the reporter nucleic acid encoding nucleic acid(s); and measuring the activation of the reporter element by one or more assays.
[0027] Response element control promoter
[0028] A response element is a short DNA sequence within a gene promoter region that binds to a specific transcription factor and can regulate the transcription of a gene. Specific response elements are specific to specific promoters. Some response elements may be bound by endogenous transcription factors. Multiple copies of the same response element may be located in different parts of the nucleotide sequence to activate different genes in response to the same stimulus. Non-limiting examples of response elements that may be introduced into the systems described herein include cAMP response elements (CRE), B recognition elements, AhR-, dioxin- or xenobiotic response elements, HIF- response elements, hormone response elements, serum response elements, retinoic acid response elements, peroxisome proliferator hormone response elements, metal response elements, DNA damage response elements, IFN-stimulated response elements, ROR response elements, glucocorticoid response elements, calcium response elements CaRE1, antioxidant response elements, p53 response elements, thyroid hormone response elements, growth hormone response elements, sterol response elements, Polycomb response elements, and vitamin D response elements.
[0029] A response element regulatory promoter nucleotide sequence is a nucleic acid region containing one or more response elements that help recruit promoters and other molecules that regulate the transcription of genes. Cells contain multiple response element regulatory nucleotide sequences that utilize endogenous proteins to regulate gene transcription. In situations where endogenous response element regulatory promoter nucleotide sequences directly regulate reporter transcription, a high level of background signal exists due to the presence of the endogenous promoter. In cells containing the system, a system that regulates reporter transcription with non-endogenous transcription factors will have an advantage over a system that regulates reporter transcription with endogenous transcription factors. One advantage of such a system would be that the background production of the reporter is lower.
[0030] In a specific embodiment, the transcription relay system of the present invention comprises a transcription factor nucleic acid comprising a reaction factor regulatory promoter nucleotide sequence and a nucleotide sequence encoding a synthetic transcription factor, wherein the reaction factor regulatory promoter nucleotide sequence is located at the 5' position relative to the nucleotide sequence encoding the synthetic transcription factor. The reaction factor regulatory promoter nucleotide sequence serves to control the expression of the synthetic transcription factor encoded by the synthetic transcription factor nucleotide sequence. In a specific embodiment, the reaction factor regulatory promoter nucleotide sequence comprises a cAMP reaction factor nucleotide sequence, an NFAT transcription factor reaction factor nucleotide sequence, an FOS promoter nucleotide sequence, a serum reaction factor nucleotide sequence, or a combination thereof. In a specific embodiment, the reaction factor regulatory promoter nucleotide sequence comprises a cAMP reaction factor nucleotide sequence. In a specific embodiment, the reaction factor regulatory promoter nucleotide sequence comprises an NFAT transcription factor reaction factor nucleotide sequence. In certain embodiments, the reaction factor regulatory promoter nucleotide sequence comprises an FOS promoter nucleotide sequence. In certain embodiments, the reaction factor regulatory promoter nucleotide sequence comprises a serum reaction factor nucleotide sequence. In certain embodiments, the reaction factor regulatory promoter nucleotide sequence comprises any combination of a cAMP reaction factor nucleotide sequence, an NFAT transcription factor reaction factor nucleotide sequence, an FOS promoter nucleotide sequence, and / or a serum reaction factor nucleotide sequence.
[0031] In certain embodiments, the response element regulatory promoter may be coupled by a transcription factor. Non-limiting examples of common transcription factors include LexA, Gal4, VP16 (derived from herpes simplex virus), heat shock factor (HSF), NFAT, CREB, or combinations thereof. The system described herein may be compatible with any transcription factor, or any combination thereof, that is generally or potentially available in reporter assays.
[0032] In certain embodiments, the response element regulatory promoter is coupled by an endogenous transcription factor. The endogenous transcription factor is a transcription factor that naturally exists in an organism, tissue, or cell. The presence of the endogenous transcription factor will depend on the system in which the transcription relay exists. In certain embodiments, the endogenous transcription factor promotes the transcription of the synthetic transcription factor at a background rate.
[0033] In certain embodiments, the transcription factor nucleic acid comprises a nucleotide sequence adjacent to the reaction factor regulatory promoter nucleic acid sequence that can be bound by a transcription repressor. The transcription repressor inhibits the transcription of the distal nucleotide sequence. Non-limiting examples of conventional transcription repressors include TetR, lac Includes inhibitors, KRAB inhibitors, and combinations thereof. The system described herein is compatible with any inhibitor, or any combination thereof, that is generally or potentially available in reporter tests.
[0034] In a specific embodiment, the transcription factor nucleic acid comprises a nucleotide sequence adjacent to the response factor regulatory promoter nucleotide sequence that extends the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor. In a specific embodiment, the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor comprises one or more sequences that reduce the translation of the synthetic transcription factor. In a specific embodiment, the one or more sequences that reduce the translation of the synthetic transcription factor comprise a secondary structure that reduces the translation of the synthetic transcription factor. In a specific embodiment, the one or more sequences that reduce the translation of the synthetic transcription factor comprise a sequence that influences binding by an RNA binding protein. In a specific embodiment, the one or more sequences that reduce the translation of the synthetic transcription factor comprise an upstream open reading frame.
[0035] Testing method
[0036] The system described above can be effectively utilized using various methods. The system is useful in methods for investigating the activity of cell signaling pathways under steady conditions and in response to physical or chemical stimuli. When a reporter element contains a UMI sequence mated to a specific reporter element, the system can be efficiently utilized in multiplexed assays.
[0037] In one non-limiting exemplary example, multiple cells are incubated in one well of a multi-well plate. Multiple cells are transfected with a reporter nucleic acid comprising a synthetic transcription factor promoter nucleotide sequence and a nucleotide sequence encoding a reporter. The cells may already contain a transcription factor nucleic acid comprising a response factor regulatory promoter nucleotide sequence and a nucleotide sequence encoding a synthetic transcription factor, or may be transfected with said transcription factor nucleic acid. Subsequently, the transfected cells are exposed to a chemical stimulus. After a sufficient amount of time has elapsed to allow the reporter gene to be expressed, the cell lysate is harvested, and the activation of said reporter gene is quantified. In the above example, if the presence of the reporter gene has increased, this would suggest that the chemical stimulus increased the activity of the transcription factor(s) binding to said response factor regulatory promoter. In certain embodiments, said transcription factor(s) binding to said response factor regulatory promoter have increased activity after a cell-signaling cascade.
[0038] In an embodiment in which the reporter gene comprises an enzyme that generates a detectable signal upon interaction with a substrate, the activation of the reporter gene can be quantified using standard assays known in the art. In an embodiment in which the reporter gene comprises a fluorescent molecule, the activation of the reporter gene can be measured by fluorescence microscopy or a fluorescent plate reader and may not require cell lysis. The fluorescent molecule is useful for measuring reporter activation in living cells. In an embodiment in which the reporter gene comprises a UMI, the mRNA is reverse transcribed, and the sequencing of the UMI is performed by next-generation sequencing technology.
[0039] In certain embodiments, the assay is performed in a multi-well format, such as a 6, 12, 24, 48, 96, or 384-well format. In certain embodiments, different test chemicals are supplied to each well, or the test chemicals are supplied to double, triple, or quadruple wells. The assay may also include one or more positive or negative control wells.
[0040] Synthetic Transcription Factor
[0041] Synthetic transcription factors are artificial proteins capable of targeting and regulating gene expression. Some synthetic transcription factors are chimeric proteins containing domains from multiple different genes. In certain embodiments, a synthetic transcription factor includes a DNA binding domain from one gene and a transcription regulatory domain from another gene.
[0042] In the methods, nucleic acids, and systems described herein, a transcription-activating polypeptide is encoded on a transcription factor nucleic acid. In certain embodiments, the transcription-activating polypeptide is a synthetic transcription factor. In certain embodiments, the synthetic transcription factor is a chimeric protein. In certain embodiments, the synthetic transcription factor comprises a DNA binding domain from a first transcription factor. In certain embodiments, the synthetic transcription factor comprises a transcription-activating domain from a second transcription factor. In certain embodiments, the first transcription factor is different from the second transcription factor.
[0043] In certain embodiments, the synthetic transcription factor has higher specificity for the synthetic transcription factor promoter nucleotide sequence than any endogenous transcription factor. In certain embodiments, the synthetic transcription factor binds to the synthetic transcription factor promoter nucleotide sequence that the endogenous promoter cannot bind to. In certain embodiments, the synthetic transcription factor produces less background than occurs when using the endogenous transcription factor.
[0044] In certain embodiments, the DNA binding domain is non-endogenous to cells containing the transcription relay system of the present invention. In certain embodiments, the DNA binding domain from the first transcription factor is from Gal 4, PPR1, LexA, Lac9, or a combination thereof. In certain embodiments, the DNA binding domain is
[0045] It includes the amino acid sequence described in ). In certain embodiments, the DNA binding domain is
[0046] It includes the amino acid sequence described in ). In certain embodiments, the DNA binding domain is
[0047] It includes the amino acid sequence described in ). In certain embodiments, the DNA binding domain is
[0048] It includes the amino acid sequence described in ). In certain embodiments, the DNA binding domain is
[0049] It includes the amino acid sequence described in ). In certain embodiments, the DNA binding domain is
[0050] It includes the amino acid sequence described in ). In certain embodiments, the DNA binding domain is
[0051] It includes the amino acid sequence described in ). In certain embodiments, the DNA binding domain is
[0052] It includes the amino acid sequence described in.
[0053] In certain embodiments, the DNA binding domain comprises an amino acid sequence variant of SEQ ID NO. 1. In certain embodiments, the amino acid sequence variant of SEQ ID NO. 1 is R15W, K23P, K23T, K23W, K23M, K23N, F68R, F68Q, L69P, L70P, Q9E, Q9A, Q9N, R15K, R15A, R15M, K18R, K18A, K18M, K23R, K23A, K23M, or a combination thereof. In certain embodiments, the amino acid sequence variant of SEQ ID NO. 1 is R15W. In certain embodiments, the amino acid sequence variant of SEQ ID NO. 1 is K23P. In certain embodiments, the amino acid sequence variant of SEQ ID NO. 1 is K23T. In certain embodiments, the amino acid sequence variant of SEQ ID NO. 1 is K23W. In certain embodiments, the amino acid sequence variant of SEQ ID NO. 1 is K23M. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is K23N. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is F68R. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is F68Q. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is L69P. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is L70P. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is Q9E. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is Q9A. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is Q9N. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is R15K. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is R15A. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is R15M. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is K18R. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is K18A.In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is K18M. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is K23R. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is K23A. In a specific embodiment, the amino acid sequence variant of SEQ No. 1 is K23M.
[0054] In a specific embodiment, the transcriptional activation domain from the second transcription factor is from VP64, p65, and Rta, and combinations thereof. In a specific embodiment, the transcriptional activation domain is
[0055] It includes the amino acid sequence described in.
[0056] In certain embodiments, the nucleic acid described herein codes for a transcription factor having a VPR amino acid sequence that is at least 90%, 95%, 97%, 98%, 99%, or 100% identical to the amino acid sequence described in SEQ No. 14. In certain embodiments, the nucleic acid described herein codes for a transcription factor having a VPR amino acid sequence that is at least 90% identical to the amino acid sequence described in SEQ No. 14. In certain embodiments, the nucleic acid described herein codes for a transcription factor having a VPR amino acid sequence that is at least 95% identical to the amino acid sequence described in SEQ No. 14. In certain embodiments, the nucleic acid described herein codes for a transcription factor having a VPR amino acid sequence that is at least 97% identical to the amino acid sequence described in SEQ No. 14. In certain embodiments, the nucleic acid described herein codes for a transcription factor having a VPR amino acid sequence that is at least 98% identical to the amino acid sequence described in SEQ No. 14. In certain embodiments, the nucleic acid described herein codes for a transcription factor having a VPR amino acid sequence that is at least 99% identical to the amino acid sequence described in SEQ No. 10. In certain embodiments, the nucleic acid described herein codes for a transcription factor having a VPR amino acid sequence that is at least 100% identical to the amino acid sequence described in SEQ ID NO. 10.
[0057] In a specific embodiment, a transcriptional activation domain on a synthetic transcription factor comprises an amino acid sequence variant that increases or decreases transcriptional activation. In a specific embodiment, the transcriptional activation domain comprising an amino acid sequence variant that increases or decreases transcriptional activation is a sequence variant of SEQ ID NO. 14.
[0058] In certain embodiments, the synthetic transcription factor encoded by the nucleic acid sequence of the transcription factor nucleic acid comprises a polypeptide sequence that destabilizes the synthetic transcription factor, also named "degron". In certain embodiments, the polypeptide sequence that destabilizes the transcription factor comprises a PEST polypeptide sequence. The PEST polypeptide sequence is a polypeptide sequence containing a plurality of amino acids, wherein the polypeptide sequence is a polypeptide sequence rich in the amino acids proline, glutamic acid, serine, and / or threonine. In certain embodiments, the polypeptide sequence that destabilizes the transcription factor comprises a CL1 polypeptide sequence. The CL1 polypeptide sequence can act as a degradation signal, and the half-life of the resulting synthetic transcription factor can be shortened. In certain embodiments, the polypeptide sequence that destabilizes the synthetic transcription factor helps reduce the background signal of the reporter.
[0059] In certain embodiments, the synthetic transcription factor comprises a GAL4-VP16 chimeric transcription factor. In certain embodiments, the transcription factor comprises a GAL4-VPR chimeric transcription factor. The sequence of the Gal4-VPR chimeric transcription factor is
[0060] Provided by the sequence described herein. In certain embodiments, the nucleic acid described herein codes for a transcription factor having an amino acid sequence that is at least 90%, 95%, 97%, 98%, 99%, or 100% identical to the amino acid sequence described in SEQ No. 10. In certain embodiments, the nucleic acid described herein codes for a transcription factor having an amino acid sequence that is at least 90% identical to the amino acid sequence described in SEQ No. 10. In certain embodiments, the nucleic acid described herein codes for a transcription factor having an amino acid sequence that is at least 95% identical to the amino acid sequence described in SEQ No. 10. In certain embodiments, the nucleic acid described herein codes for a transcription factor having an amino acid sequence that is at least 97% identical to the amino acid sequence described in SEQ No. 10. In certain embodiments, the nucleic acid described herein codes for a transcription factor having an amino acid sequence that is at least 98% identical to the amino acid sequence described in SEQ No. 10. In certain embodiments, the nucleic acid described herein codes for a transcription factor having an amino acid sequence that is at least 99% identical to the amino acid sequence described in SEQ No. 10. In certain embodiments, the nucleic acid described herein codes for a transcription factor having an amino acid sequence that is at least 100% identical to the amino acid sequence described in SEQ ID NO. 10.
[0061] In a specific embodiment, the synthetic transcription factor comprises a Gal4 DNA binding domain provided by the amino acid sequence described in SEQ ID NO. 1. In a specific embodiment, the synthetic transcription factor comprises a DNA binding domain having an amino acid sequence that is at least 90%, 95%, 97%, 98%, 99%, or 100% identical to the amino acid sequence described in SEQ ID NO. 1. In a specific embodiment, the synthetic transcription factor comprises a DNA binding domain having an amino acid sequence that is at least 90% identical to the amino acid sequence described in SEQ ID NO. 1. In a specific embodiment, the synthetic transcription factor comprises a DNA binding domain having an amino acid sequence that is at least 95% identical to the amino acid sequence described in SEQ ID NO. 1. In a specific embodiment, the synthetic transcription factor comprises a DNA binding domain having an amino acid sequence that is at least 97% identical to the amino acid sequence described in SEQ ID NO. 1. In a specific embodiment, the synthetic transcription factor comprises a DNA binding domain having an amino acid sequence that is at least 98% identical to the amino acid sequence described in SEQ ID NO. 1. In a specific embodiment, the synthetic transcription factor comprises a DNA binding domain having an amino acid sequence that is at least 99% identical to the amino acid sequence described in SEQ ID NO. 1. In a specific embodiment, the synthetic transcription factor comprises a DNA binding domain having an amino acid sequence that is at least 100% identical to the amino acid sequence described in SEQ ID NO. 1.
[0062] In certain embodiments, the synthetic transcription factor is
[0063] It includes a transcriptional activation domain from VP64 provided by the amino acid sequence described in. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 90%, 95%, 97%, 98%, 99%, or 100% identical to the amino acid sequence described in SEQ ID NO. 11. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 90% identical to the amino acid sequence described in SEQ ID NO. 11. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 95% identical to the amino acid sequence described in SEQ ID NO. 11. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 97% identical to the amino acid sequence described in SEQ ID NO. 11. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 98% identical to the amino acid sequence described in SEQ ID NO. 11. In a specific embodiment, the synthetic transcription factor comprises a transcriptional activation domain having an amino acid sequence that is at least 99% identical to the amino acid sequence described in SEQ ID NO. 11. In a specific embodiment, the synthetic transcription factor comprises a transcriptional activation domain having an amino acid sequence that is at least 100% identical to the amino acid sequence described in SEQ ID NO. 11.
[0064] In certain embodiments, the synthetic transcription factor is
[0065] It includes a transcriptional activation domain from p65 provided by the amino acid sequence described in. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 90%, 95%, 97%, 98%, 99%, or 100% identical to the amino acid sequence described in SEQ ID NO. 12. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 90% identical to the amino acid sequence described in SEQ ID NO. 12. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 95% identical to the amino acid sequence described in SEQ ID NO. 12. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 97% identical to the amino acid sequence described in SEQ ID NO. 12. In certain embodiments, the synthetic transcription factor includes a transcriptional activation domain having an amino acid sequence that is at least 98% identical to the amino acid sequence described in SEQ ID NO. 12. In a specific embodiment, the synthetic transcription factor comprises a transcriptional activation domain having an amino acid sequence that is at least 99% identical to the amino acid sequence described in SEQ ID NO. 12. In a specific embodiment, the synthetic transcription factor comprises a transcriptional activation domain having an amino acid sequence that is at least 100% identical to the amino acid sequence described in SEQ ID NO. 12.
[0066] In certain embodiments, the synthetic transcription factor is
[0067] It includes a transcription activation domain from Rta provided by the amino acid sequence described in. In certain embodiments, the synthetic transcription factor includes a transcription activation domain having an amino acid sequence that is at least 90%, 95%, 97%, 98%, 99%, or 100% identical to the amino acid sequence described in SEQ ID NO. 13. In certain embodiments, the synthetic transcription factor includes a transcription activation domain having an amino acid sequence that is at least 90% identical to the amino acid sequence described in SEQ ID NO. 13. In certain embodiments, the synthetic transcription factor includes a transcription activation domain having an amino acid sequence that is at least 95% identical to the amino acid sequence described in SEQ ID NO. 13. In certain embodiments, the synthetic transcription factor includes a transcription activation domain having an amino acid sequence that is at least 97% identical to the amino acid sequence described in SEQ ID NO. 13. In certain embodiments, the synthetic transcription factor includes a transcription activation domain having an amino acid sequence that is at least 98% identical to the amino acid sequence described in SEQ ID NO. 13. In a specific embodiment, the synthetic transcription factor comprises a transcriptional activation domain having an amino acid sequence that is at least 99% identical to the amino acid sequence described in SEQ ID NO. 13. In a specific embodiment, the synthetic transcription factor comprises a transcriptional activation domain having an amino acid sequence that is at least 100% identical to the amino acid sequence described in SEQ ID NO. 13.
[0068] Synthetic transcription factor promoter nucleotide sequence
[0069] A synthetic transcription factor promoter nucleotide sequence is a sequence of nucleic acid that can be bound by a synthetic transcription factor. In certain embodiments, the synthetic transcription factor nucleotide sequence is not bound by an endogenous transcription factor. The synthetic transcription factor promoter nucleotide sequence assists in the recruitment of the synthetic transcription factor to activate the transcription of a reporter molecule. The reporter molecule is encoded on the nucleic acid located at the 3' of the synthetic transcription factor promoter nucleotide sequence.
[0070] In the methods, nucleic acids, and systems described herein, a synthetic transcription factor promoter nucleotide sequence is encoded on a reporter nucleic acid. The synthetic transcription factor promoter nucleotide sequence may be bound by a synthetic transcription factor encoded on the transcription factor nucleic acid. The synthetic transcription factor promoter nucleotide sequence is located at the 5' of the nucleotide sequence encoding the reporter. In certain embodiments, the synthetic transcription factor promoter nucleotide sequence is not bound by an endogenous transcription factor. In certain embodiments, the synthetic transcription factor is highly specific to the synthetic transcription factor promoter nucleotide sequence.
[0071] In certain embodiments, the synthetic transcription factor promoter nucleotide sequence may be bound to Gal4, PPR1, Lac9, or LexA. In certain embodiments, the synthetic transcription factor may be bound to a polypeptide comprising the amino acid sequence described in SEQ ID NO. 1.
[0072] In certain embodiments, the synthetic transcription factor promoter nucleotide sequence may be bound to an amino acid sequence variant of Gal4, PPR1, Lac9, or LexA. In certain embodiments, the synthetic transcription factor promoter nucleotide sequence may be bound to an amino acid sequence variant of Sequence No. 1.
[0073] Reporter element
[0074] The reporter nucleic acid comprises at least a regulatory element that can be bound by a synthetic transcription factor and a nucleotide sequence encoding the reporter. The nucleotide sequence encoding the reporter is located downstream of the regulatory element that can be bound by the synthetic transcription factor. The synthetic transcription factor regulates the expression of the reporter.
[0075] In certain embodiments, the nucleotide sequence encoding the reporter comprises a reporter gene. In certain embodiments, the reporter gene encodes a reporter selected from fluorescent proteins, luciferase proteins, beta-galactosidase, beta-glucuronidase, chloramphenicol acetyltransferase, and secreted placental alkaline phosphatase. These reporter proteins may be tested for specific enzyme activity, or, in the case of fluorescent reporters, for fluorescence emission. In certain embodiments, the fluorescent protein comprises green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), or cyan fluorescent protein (CFP).
[0076] In certain embodiments, the nucleotide sequence encoding the reporter gene includes a nucleotide sequence encoding a unique sequence identifier (UMI). In certain embodiments, the UMI is unique to the test polypeptide, and the test polypeptide is encoded by the reporter nucleic acid. Generally, the length of the UMI will be 8 to 20 nucleotides, but may be longer. In certain embodiments, the length of the UMI is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleotides. In certain embodiments, the length of the UMI is 8 nucleotides. In certain embodiments, the length of the UMI is 9 nucleotides. In certain embodiments, the length of the UMI is 10 nucleotides. In certain embodiments, the length of the UMI is 11 nucleotides. In a specific embodiment, the length of the UMI is 12 nucleotides. In a specific embodiment, the length of the UMI is 13 nucleotides. In a specific embodiment, the length of the UMI is 14 nucleotides. In a specific embodiment, the length of the UMI is 15 nucleotides. In a specific embodiment, the length of the UMI is 16 nucleotides. In a specific embodiment, the length of the UMI is 17 nucleotides. In a specific embodiment, the length of the UMI is 18 nucleotides. In a specific embodiment, the length of the UMI is 19 nucleotides. In a specific embodiment, the length of the UMI is 20 nucleotides. In a specific embodiment, the length of the UMI is more than 20 nucleotides.
[0077] The system described herein may utilize a number of different regulatory sequences that control the activation of a reporter gene through the binding of a synthetic transcription factor. The regulatory sequences are those that can be bound by a synthetic transcription factor polypeptide. Generally, the regulatory sequences will be configured to be located at the 5' for the UMI, the reporter gene, or both. In certain embodiments, the regulatory sequences comprise Gal4-, PPR1-, or LexA-UAS, which can be bound by a synthetic transcription factor.
[0078] In certain embodiments, the reporter comprises a fluorescent protein, a luciferase protein, a beta-galactosidase, a beta-glucuronidase, a chloramphenicol acetyltransferase, or a secreted placental alkaline phosphatase, and a UMI. In certain embodiments, the UMI is encoded on the reporter nucleic acid located at the 5' of the fluorescent protein, the luciferase protein, the beta-galactosidase, the beta-glucuronidase, the chloramphenicol acetyltransferase, or the secreted placental alkaline phosphatase. In certain embodiments, a nucleotide sequence encoding the nucleotide sequence encoding the fluorescent protein, the luciferase protein, the beta-galactosidase, the beta-glucuronidase, the chloramphenicol acetyltransferase, or the secreted placental alkaline phosphatase is located at the 5' of the UMI.
[0079] Since the transcription of the UMI specifies the association between a specific relay system and a reporter, the UMI allows for the multiplexing of different transcription relay systems within the same assay. The length of the UMI may be any length that allows for the multiplexing of different transcription relay systems within the same assay through sufficient variability. The length must be sufficient to distinguish between at least 100, 500, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, or 10,000 transcription relay targets. In certain embodiments, the different transcription relay systems will exist in different cells. In certain embodiments, the different transcription relay systems will exist in the same cell.
[0080] The reporter element may additionally include a 5' UTR, a 3' UTR, or both. The UTR may be heterogeneous with respect to the reporter element.
[0081] Reporter activation
[0082] The activation of reporter molecules can be measured using standard assays that detect luciferase protein, beta-galactosidase protein, beta-glucuronidase protein, chloramphenicol acetyltransferase protein, and secreted placental alkaline phosphatase protein. Generally, this is an enzymatic assay in which a detectable signal is generated based on the detectable signal. For example, luciferase expression can be measured by a luminescence analyzer in the presence of a luciferase substrate. Fluorescent reporters do not require a substrate, and the signal can be measured by fluorescence microscopy or a fluorescent plate reader. Fluorescent reporters are particularly useful for measuring reporter activation in living cells.
[0083] In an embodiment where the reporter molecule comprises a unique RNA sequence, reporter activation may be measured in any suitable manner that allows sequencing of the unique RNA sequence, and a method that allows sequencing in multiple ways is preferred. The method comprises a high-throughput sequencing method capable of generating information on at least about 100,000, 1,000,000, 10,000,000, or 100,000,000 DNA or RNA bases within a 24-hour period. In a specific embodiment, the sequence of the unique RNA sequence is determined using next-generation sequencing technology. Next-generation sequencing includes many types of sequencing, e.g., pyrosequencing, synthetic sequencing, single molecule sequencing, next-generation sequencing, nanopore sequencing, ligation sequencing, or hybridization sequencing. Next-generation sequencing platforms include those commercially available from Illumina (RNA-Seq) and Helicos (Digital Gene Expression or "DGE"). Next-generation sequencing is 1) literature [Margulies et al., Nature (2005) 437:376-380 (2005)] and U.S. Patents No. 7,244,559; No. 7,335,762; No. 7,211,390; No. 7,244,567; No. 7,264,929; No. 7,323,305, including but not limited to the methods and apparatus described in 454 / Roche Lifesciences; 2) U.S. Application Serial No. 11 / 167046, U.S. Patents No. 7501245; No. 7491498; No. 7,276,720; and U.S. Patent Application Publications No. US20090061439; No. US20080087826; No. US20060286566; Helicos Biosciences Corporation (Cambridge, Massachusetts, USA), as described in US No. 20060024711; US No. 20060024678; US No. 20080213770; and US No. 20080103058; 3) Applied Biosystems (e.g., SOLiD sequencing); 4) Dover Systems (e.g., Polonator G.007 sequencing); 5) Illumina, Inc., as described in US No. 5,750,341; No. 6,306,597; and No. 5,969,119; and 6) US No. 7,462,452; Includes, but not limited to, those commercialized by Pacific Biosciences as described in US Applications No. 7,476,504; No. 7,405,281; No. 7,170,050; No. 7,462,468; No. 7,476,503; No. 7,315,019; No. 7,302,146; No. 7,313,308; and US Applications Publication No. US20090029385; No. US20090068655; No. US20090024331; and No. US20080206764.
[0084] Marker
[0085] In certain embodiments, the nucleic acid described herein further comprises one or more additional genes encoding a selection polypeptide or a marking polypeptide. In certain embodiments, the nucleic acid described herein further comprises one or more additional genes encoding a polypeptide that confers antibiotic resistance to transfected cells. For example, the nucleic acid may include a selection marker, such as an antibiotic resistance gene conferring antibiotic resistance such as neomycin / G418 resistance, puromycin resistance, zeocin resistance, or blasticidin resistance. In certain embodiments, the nucleic acid described herein further comprises one or more additional genes encoding a polypeptide containing an epitope tag expressed on the cell surface. This allows transfected cells to be collected using the described nucleic acid by performing affinity purification or cell sorting. In certain embodiments, the epitope tag includes a c-Myc tag, a hemagglutinin (HA) tag, a histidine tag, a V5 tag, or a FLAG tag. In certain embodiments, the nucleic acid described herein further comprises one or more additional promoterless genes encoding a fluorescent polypeptide. Such genes are useful when transfection is intended to induce integration and is targeted for a specific location or landing pad. In such cases, the "landing pad" within the cell genome contains a promoter that can compensate for the lack of a promoter in the promoterless gene and induce the expression of the promoterless gene only when the promoterless gene is integrated into the intended genomic location. Cells that have been correctly integrated can be selected by flow cytometry and cell sorting. Furthermore, this type of marker can ensure that only a single copy of the intended nucleic acid is integrated into the genome, which helps avoid ectopic overexpression.In certain embodiments, the nucleic acid encoding the bait polypeptide comprises a gene encoding a polypeptide that confers antibiotic resistance to transfected cells; a gene encoding a polypeptide containing an epitope tag expressed on the cell surface; or a promoter-free gene encoding a fluorescent polypeptide.
[0086] cell
[0087] Cells useful for the methods described herein are generally cells that can be readily transgenic with one or more exogenous nucleic acids encoding synthetic transcription factors and reporter elements. Systemic nucleic acid(s) encoding synthetic transcription factors and reporter elements may be transfected or transduced into a suitable cell line using methods known in the art, such as calcium phosphate transfection, lipid-based transfection (e.g., Lipofectamine™, Lipofectamine-2000™, Lipofectamine-3000™, or Fugene® HD), electroporation, or viral transfection. The cells may also be a population of the same type of cells grown in a suitable cell culture vessel until full growth or nearly full growth.
[0088] In certain embodiments, the cells used comprise a stable incorporation of a nucleic acid encoding a synthetic transcription factor, a nucleic acid containing a reporter element, or both. Stable cell lines may be prepared using random incorporation of a linearized plasmid, viral or transposon-designated incorporation, or designated incorporation utilizing site-specific recombination between, for example, AttP and AttB sites. In certain embodiments, one of the nucleic acids is encoded at a stable landing site, such as, for example, the AAVS1 site.
[0089] In certain embodiments, the cell or cell population used in the system is a eukaryotic cell. In certain embodiments, the cell or cell population is a mammalian cell. In certain embodiments, the cell or cell population is a human cell. In certain embodiments, the cell or cell population is SH-SY5Y, human neuroblastoma; Hep G2, human Caucasian hepatocellular carcinoma; 293 (also known as HEK 293), human embryonic kidney; RAW 264.7, mouse monocyte macrophage; HeLa, human cervical epithelial carcinoma; MRC-5 (PD 19), human fetal lung; A2780, human ovarian carcinoma; CACO-2, human Caucasian colorectal adenocarcinoma; THP 1, human monocyte leukemia; A549, human Caucasian lung carcinoma; MRC-5 (PD 30), human fetal lung; MCF7, human Caucasian breast adenocarcinoma; SNL 76 / 7, mouse SIM lineage embryonic fibroblast; C2C12, mouse C3H myomyoblast; Jurkat E6.1, Human leukemia T-cell lymphoblast; U937, Human Caucasian histiocytic lymphoma; L929, Mouse C3H / An connective tissue; 3T3 L1, Mouse embryo; HL60, Human Caucasian promyelocytic leukemia; PC-12, Rat adrenopheochromocytoma; HT29, Human Caucasian colorectal adenocarcinoma; OE33, Human Caucasian esophageal carcinoma; OE19, Human Caucasian esophageal carcinoma; NIH 3T3, Mouse Swiss NIH embryo; MDA-MB-231, Human Caucasian breast adenocarcinoma; K562, Human Caucasian chronic myeloid leukemia; U-87 MG, Human glioblastoma astrocytoma; MRC-5 (PD 25), Human fetal lung; A2780cis, Human ovarian carcinoma; B9, Mouse B-cell hybridoma; CHO-K1, Chinese hamster ovary; MDCK, Cocker Spaniel kidney; 1321N1, human cerebral astrocytoma; A431, human squamous cell carcinoma; ATDC5, derived from mouse 129 teratoma AT805; RCC4 PLUS VECTOR ALONE, renal cell carcinoma cell line RCC4 stably transfected with a pcDNA3 co-expression vector conferring neomycin resistance; HUVEC (S200-05n), human pre-screened umbilical vein endothelial cells (HUVEC); neonate; Vero, African green monkey kidney; RCC4 PLUS VHL, renal cell carcinoma cell line RCC4 stably transfected with pcDNA3-VHL; Fao, rat hepatoma; J774A.1, mouse BALB / c monocyte macrophage; MC3T3-E1, mouse C57BL / 6 cranial duct; J774.2, Mouse BALB / c monocyte macrophage; PNT1A, human post-pubertal prostate normal immortalized with SV40; U-2 OS, human osteosarcoma; HCT 116, human colon carcinoma; MA104, African green monkey kidney; BEAS-2B, human bronchial epithelial cell, normal; NB2-11, rat lymphoma; BHK 21 (clone 13), Syrian hamster kidney; NS0, mouse myeloma; Neuro 2a, mouse albino neuroblastoma; SP2 / 0-Ag14, mouse x mouse myeloma, non-proliferative; T47D, human breast tumor; 1301, human T-cell leukemia; MDCK-II, dog Cocker Spaniel kidney; PNT2, human prostate normal immortalized with SV40; PC-3, human Caucasian prostate adenocarcinoma; TF1, human erythroleukemia; COS-7, African green monkey kidney, SV40 transgenic; MDCK, dog Cocker Spaniel kidney; HUVEC (200-05n), human umbilical vein endothelial cell (HUVEC); neonate; NCI-H322, human Caucasian bronchioloalveolar carcinoma; SK.N.SH, human Caucasian neuroblastoma; LNCaP.FGC, Human Caucasian Prostate Carcinoma; OE21, Human Caucasian Esophageal Squamous Cell Carcinoma; PSN1, Human Pancreatic Adenocarcinoma; ISHIKAWA, Human Asian Endometrial Adenocarcinoma; MFE-280, Human Caucasian Endometrial Adenocarcinoma; MG-63, Human Osteosarcoma; RK 13, Rabbit Kidney, BVDV Negative; EoL-1 Cells, Human Eosinophilic Leukemia; VCaP, Human Prostate Cancer Metastasis; tsA201, Human Embryonic Kidney, SV40 Transgenic; CHO, Chinese Hamster Ovary; HT 1080, Human Fibrosarcoma; PANC-1, Human Caucasian Pancreas; Saos-2, Human Primary Osteogenic Sarcoma; Fibroblast Growth Medium (116K-500), Fibroblast Growth Medium Kit; ND7 / 23, Mouse Neuroblastoma x Rat Neuron Hybrid; SK-OV-3, Human Caucasian Ovarian Adenocarcinoma; COV434, Human ovarian granulosa cell tumor; Hep 3B, Human hepatocellular carcinoma; Vero (WHO), African green monkey kidney; Nthy-ori 3-1, Human thyroid follicular epithelial cell; U373 MG (Uppsala), Human glioblastoma astrocytoma; A375, Human malignant melanoma; AGS, Human Caucasian gastric adenocarcinoma; CAKI 2, Human Caucasian renal carcinoma; COLO 205, Human Caucasian colon adenocarcinoma; COR-L23, Human Caucasian pulmonary large cell carcinoma; IMR 32, Human Caucasian neuroblastoma; QT 35, Quail Japanese fibrosarcoma; WI 38, Human Caucasian fetal lung; HMVII, Human vaginal malignant melanoma; HT55, Human colon carcinoma; TK6, Human lymphoblast, thymitine kinase heterozygous; SP2 / 0-AG14 (AC-FREE), mouse x mouse hybridoma non-secretory, serum-free, animal component (AC)-free; AR42J, or rat exocrine pancreatic tumor, or any combination thereof.
[0090] The present invention describes a cell and a cell line comprising a transcription factor nucleic acid comprising a nucleotide sequence of a response factor regulatory promoter and a nucleotide sequence encoding a synthetic transcription factor, wherein the response factor regulatory promoter nucleotide sequence is located at the 5' position relative to the nucleotide sequence encoding the synthetic transcription factor. In certain embodiments, the cell line is a mammalian cell line. In certain embodiments, the response factor regulatory promoter is a cAMP response factor nucleotide sequence, an NFAT transcription factor response factor nucleotide sequence, an FOS promoter nucleotide sequence, or a serum response factor nucleotide sequence. In certain embodiments, the response factor regulatory promoter is an NFAT response factor regulatory promoter. In a specific embodiment, the cell line comprises a reporter nucleic acid comprising a synthetic transcription factor promoter nucleotide sequence and a nucleotide sequence encoding a reporter, wherein the synthetic transcription factor promoter nucleotide sequence is located at the 5' with respect to the nucleotide sequence encoding the reporter, and the synthetic transcription factor promoter nucleotide sequence can be coupled by the synthetic transcription factor.
[0091] In certain embodiments, the cell line contains high basal reporter activity. In certain embodiments, the high basal reporter activity is at least about 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% greater than the background, where the background is the level of reporter activity observed for a cell or cell line that does not contain a reporter. For such comparison, generally, the cell or cell line used as a comparison group will be the parent cell for the cell line containing the reporter (e.g., HEK293 containing a reporter versus HEK293 not containing a reporter).
[0092] In certain embodiments, the cell line possesses high basal reporter activity. In certain embodiments, the high basal reporter activity is at least about 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 15x, 20x, 25x, 30x, 32x, 50x, 75x, 100x, 200x, 500x, 750x, 1,000x, 2,000x, 5,000x, 10,000x, or 20,000x greater than the background, where the background is the level of reporter activity observed for a cell or cell line that does not contain a reporter. In certain embodiments, the cell line possesses high basal reporter activity. In certain embodiments, high basal reporter activity is at least about 30x greater than the background, where the background is the level of reporter activity observed for cells or cell lines that do not contain a reporter. In certain embodiments, high basal reporter activity is at least about 32x greater than the background, where the background is the level of reporter activity observed for cells or cell lines that do not contain a reporter. For such comparisons, generally, the cells or cell lines used as a comparison group will be the parent cells for the cell lines containing a reporter (e.g., HEK293 containing a reporter versus HEK293 not containing a reporter).
[0093] In certain embodiments, the cell line includes low variability in basal reporter activity. In certain embodiments, low variability in basal reporter activity is a biological coefficient of variation of about 0.6 or less. In certain embodiments, low variability in basal reporter activity is a biological coefficient of variation of about 0.5 or less. In certain embodiments, low variability in basal reporter activity is a biological coefficient of variation of about 0.4 or less. In certain embodiments, low variability in basal reporter activity is a biological coefficient of variation of about 0.3 or less. In certain embodiments, low variability in basal reporter activity is a biological coefficient of variation of about 0.2 or less. In certain embodiments, low variability in basal reporter activity is a biological coefficient of variation of about 0.1 or less.
[0094] Without being bound by theory, reduced variability and high levels of basal activity can be obtained by selecting a clonal cell line comprising at least two, three, four, five, or more copies of a transcription factor nucleic acid comprising a response factor regulatory promoter nucleotide sequence and a nucleotide sequence encoding a synthetic transcription factor, wherein the response factor regulatory promoter nucleotide sequence is located at the 5' position relative to the nucleotide sequence encoding the synthetic transcription factor. In certain embodiments, the response factor regulatory promoter is a cAMP response factor nucleotide sequence, an NFAT transcription factor response factor nucleotide sequence, an FOS promoter nucleotide sequence, or a serum response factor nucleotide sequence. In certain embodiments, the response factor regulatory promoter is an NFAT response factor regulatory promoter. In certain embodiments, the cell line comprises only one copy of a reporter nucleic acid comprising a synthetic transcription factor promoter nucleotide sequence and a nucleotide sequence encoding a reporter. In certain embodiments, the cell line comprises only two copies of a reporter nucleic acid comprising a synthetic transcription factor promoter nucleotide sequence and a nucleotide sequence encoding a reporter. In certain embodiments, the cell line comprises a reporter nucleic acid comprising a synthetic transcription factor promoter nucleotide sequence and a nucleotide sequence encoding a reporter, which is maintained in a non-integrated or episomal state. In certain embodiments, the cell line further comprises a nucleic acid encoding cDNA of a cell signaling protein or, alternatively, an intron-free version. In certain embodiments, the cell signaling protein is a GPCR or a GPCR subunit.
[0095] In certain embodiments, the cell contains nucleic acids encoding a member of the G protein-coupled receptor family. A G protein-coupled receptor (GPCR), also known as a 7-(trans-)-transmembrane domain receptor, is a ligand-binding cell surface signaling protein. When a ligand binds to a GPCR, it causes a structural change in the GPCR, thereby enabling it to function as a guanine nucleotide exchange factor (GEF). Subsequently, the GPCR can activate the associated G protein by exchanging the GDP bound to the G protein for GTP. Subsequently, the α subunit of the G protein, along with the bound GTP, dissociates from the β and γ subunits and can further affect intracellular signaling proteins or target functional proteins directly, depending on the α subunit type (Gα, Gαi / o, Gαq / 11, Gα12 / 13). There are at least about 800 GPCRs encoded in the human genome, which are broadly divided into classes A, B, and C, and can be used in the system of the present invention. In certain embodiments, nucleic acids encoding G protein-coupled receptor family members may be incorporated into the genome. In certain embodiments, nucleic acids encoding G protein-coupled receptor family members may be maintained by episomes.
[0096] In certain embodiments, the cell contains nucleic acids encoding a member of the receptor tyrosine kinase family. Receptor tyrosine kinases (RTKs) are high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. Receptor tyrosine kinases have been shown to play a significant role not only in the development and progression of normal cellular processes but also in the development of many types of cancer. There are numerous classes and any members of RTKs available for use in the systems described herein. In certain embodiments, RTKs include RTK class I (EGF receptor family) (ErbB family); RTK class II (insulin receptor family); RTK class III (PDGF receptor family); RTK class IV (VEGF receptor family); RTK class V (FGF receptor family); RTK class VI (CCK receptor family); RTK class VII (NGF receptor family); RTK class VIII (HGF receptor family); RTK class IX (Eph receptor family); RTK class X (AXL receptor family); RTK class XI (TIE receptor family); Includes RTK class XII (RYK receptor family); RTK class XIII (DDR receptor family); RTK class XIV (RET receptor family); RTK class XV (ROS receptor family); RTK class XVI (LTK receptor family); RTK class XVII (ROR receptor family); RTK class XVIII (MuSK receptor family); RTK class XIX (LMR receptor); or RTK class XX (undetermined) members. In certain embodiments, nucleic acids encoding RTK family members may be incorporated into the genome. In certain embodiments, nucleic acids encoding RTK family members may be maintained by episomes.
[0097] The present invention also describes mammalian cell lines containing NFAT response elements. In certain embodiments, mammalian cell lines containing NFAT response elements include cb29.
[0098] The present invention also describes mammalian cell lines containing NFAT response elements. In certain embodiments, mammalian cell lines containing NFAT response elements include cb37.
[0099] How to use the system
[0100] The polynucleotide sequence of the present invention can be used for transfection into cells. Transfection can be achieved without limitation by various transfection agents, including lipopectin, calcium phosphate precipitation, viral transduction, or electroporation. Transfection may be transient or stable. In embodiments where the transfection is stable, the stably transfected cells may be frozen or stored for future use.
[0101] In certain embodiments, a single nucleic acid relay system is transfected into a cell population. In certain embodiments, 1, 2, 3, 4, 5, 10, 100, or more nucleic acid relay systems are transfected into a cell population. In certain embodiments, two nucleic acid relay systems are transfected into a cell population. In certain embodiments, three nucleic acid relay systems are transfected into a cell population. In certain embodiments, four nucleic acid relay systems are transfected into a cell population. In certain embodiments, five nucleic acid relay systems are transfected into a cell population. In certain embodiments where a cell population is transfected into multiple nucleic acid relay systems, the multiple nucleic acid relay systems include different response element regulatory promoters. In certain embodiments where the multiple nucleic acid relay systems include different response element regulatory promoters, the multiple nucleic acid relay systems include different reporters. In certain embodiments, the different reporters include UMIs.
[0102] A cell population transfected with the nucleic acid of the present invention may be of any size. In certain embodiments, the cell population comprises 1,000, 10,000, 100,000, 1,000,000, 10,000,000 or more cells. In certain embodiments, at least about 1,000 or more cells are transfected into one or more transcription relay systems. In certain embodiments, at least about 10,000 or more cells are transfected into one or more transcription relay systems. In certain embodiments, at least about 100,000 or more cells are transfected into one or more transcription relay systems. In certain embodiments, at least about 1,000,000 or more cells are transfected into one or more transcription relay systems. In certain embodiments, at least about 10,000,000 or more cells are transfected into one or more transcription relay systems.
[0103] In certain embodiments, the nucleic acid system of the present invention may be used in a multi-well plate experiment. Non-limiting examples of multi-well plates compatible with the nucleic acid relay system of the present invention include 6, 12, 24, 48, 96, 384, or 1,536-well plates. In certain embodiments, each well of the multi-well plate contains a population of cells transfected with a single transcription relay system. In certain embodiments, each well of the multi-well plate contains a population of cells transfected with multiple transcription relay systems. In certain embodiments, each well contains multiple cell populations in which each cell population is transfected with a single nucleic acid relay system. In certain embodiments, each well contains multiple cell populations in which each cell population is transfected with multiple nucleic acid relay systems.
[0104] In certain embodiments, a test agent is applied to cells transfected with the transcription relay system of the present invention. In certain embodiments, the level of transcriptional activation of a reporter molecule is measured after the cells are contacted by the test agent. In certain embodiments, the test agent is a chemical, a small molecule, a biological molecule, a polypeptide, a polynucleotide, an aptamer, or any combination thereof. In certain embodiments, a single test agent is applied to a cell population. In certain embodiments, multiple test agents are applied to a cell population.
[0105] In certain embodiments, the transcription relay system of the present invention is adapted to measure the response of a GPCR to a test agent. The nucleic acid system of the present invention may be adapted for use with any GPCR receptor. In certain embodiments, the transcription relay system is adapted for use with a GPCR receptor by utilizing a cAMP response element regulatory promoter. Non-limiting examples of GPCRs include the 5-hydroxytryptamine receptor, acetylcholine receptor, adenosine receptor, adrenergic receptor, angiotensin receptor, apelin receptor, bile acid receptor, bombesin receptor, bradykinin receptor, cannabinoid receptor, kemerin receptor, chemokine receptor, cholecystokinin receptor, dopamine receptor, endothelin receptor, formylpeptide receptor, free fatty acid receptor, galanin receptor, ghrelin receptor, glycoprotein hormone receptor, gonadotropin-releasing hormone receptor, GPR18, GPR55, GPR119.
[0106] G protein-coupled estrogen receptor, histamine receptor, hydroxycarboxylic acid receptor, cispeptide receptor, leukotriene receptor, LPA receptor, S1P receptor, melanin enrichment hormone receptor, melanocortin receptor, melatonin receptor, motilin receptor, Neuromedin U receptor, neuropeptide FF / neuropeptide AF receptor, neuropeptide S receptor, neuropeptide W / neuropeptide B receptor, neuropeptide Y receptor, neurotensin receptor, opioid receptor, opsin receptor, orexin receptor, oxoglutarate receptor, P2Y receptor, platelet-activating factor receptor, prokinetic receptor, prolactin-releasing peptide receptor, prostanoid receptor, proteinase-activated receptor, QRFP receptor, relaxin family peptide receptor, somatostatin receptor, succinate receptor, tachykinin receptor, thyrotropin-releasing hormone receptor, trace amine receptor, urotensin receptor, vasopressin and Oxytocin receptor, calcitonin receptor, corticotropin-releasing factor receptor, glucagon receptor family, parathyroid hormone receptor, VIP and PACAP receptors, calcium-sensing receptor, GABA B It includes receptors, metabolic glutamate receptors, taste 1 receptors, frizled class receptors, adhesion class GPCRs, orphan receptors, and any combination thereof.
[0107] The nucleic acid of the present invention is compatible with a number of vectors conventional in the art. Non-limiting examples of vectors include genome integration vectors, episomal vectors, plasmids, viral vectors, cosmids, bacterial artificial chromosomes, and yeast artificial chromosomes. Non-limiting examples of viral vectors compatible with the nucleic acid of the present invention include vectors derived from lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses. In certain embodiments, the nucleic acid of the present invention is present on a vector comprising a sequence directing site-specific integration to a defined location in the genome or a limited set of sites (e.g., AttP-AttB recombination).
[0108] In certain embodiments, a transcription relay system as described herein is contained within a single vector. In certain embodiments, the single vector is transiently transfected into a cell. In certain embodiments, the single vector is stably transfected into a cell.
[0109] In a specific embodiment, the transcription relay system is divided across two vectors. In a specific embodiment, a transcription factor nucleic acid comprising a nucleotide sequence of a reaction factor regulatory promoter and a nucleotide sequence encoding a synthetic transcription factor is introduced into a first vector, and a reporter nucleic acid comprising a nucleotide sequence of a synthetic transcription factor promoter and a nucleotide sequence encoding a reporter is introduced into a second vector. In a specific embodiment, the first vector and the second vector are transiently transfected into a cell. In a specific embodiment, the first vector is transfected into a cell stably. In a specific embodiment, the first vector is transfected into a cell stably, and the second vector is transiently transfected into a cell. In a specific embodiment, the first vector is transiently transfected into a cell, and the second vector is transfected into a cell stably.
[0110] Vectors comprising a vector containing the transcription relay system or a part thereof described herein may be constructed using a number of widely known molecular biology techniques. Detailed protocols for a number of such methods, including amplification, cloning, mutagenesis, transformation, etc., are described in, for example, the literature [Ausubel et al. Current Protocols in Molecular Biology (supplemented through 2012) John Wiley & Sons, New York 10 ("Ausubel")]; [Sambrook et al. Molecular Cloning - A Laboratory Manual (4th Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2012 ("Sambrook")]; and [Abelson et al. Guide to Molecular Cloning Techniques (Methods in Enzymology) volume 152 Academic Press, Inc., San Diego, CA ("Abelson")].
[0111] Examples
[0112] The following exemplary examples illustrate embodiments of the composition and method described herein and are not limited in any way.
[0113] Examples 1 - CRE Exemplary for activation GPCR Receptor screen
[0114] In this embodiment, Fig. 1a and 1b Potential compounds that induce GPCR signaling are screened using a transcription relay system containing nucleic acids as configured in [formula]. In the case of this embodiment, Fig. 1aThe nucleic acid contains cAMP response factor (CRE) activation, which results in the expression of the synthetic transcription factor Gal4-VPR (including the Gal4 DNA binding domain and the chimeric activation domain VP64-p65-Rta). Fig. 1b The nucleic acid contains a promoter that can be bound by the Gal4-VPR synthetic transcription factor and activated, which leads to the expression of reporter elements including the luciferase gene and the gene encoding UMI. The cells used are Fig. 1a and 1b It includes stably integrated nucleic acid(s) encoding the system and a given GPCR. Each UMI is associated with a given GPCR, allowing CRE expression to be mapped to a specific GPCR. This enables the assay to be multiplexed.
[0115] On Day 1, cells are plated in DMEM at a density of 35,000 cells / well in a 96-well assay plate. On Day 2, the medium is replaced with 0.5% FBS + DMEM. On Day 3, the medium is removed, and the test compound is added to 25 µl of Opti-mem at the desired concentration. After approximately 4 hours, the medium is removed and replaced with lysis buffer for RNA extraction. RNA is extracted using a standard method or kit, followed by quantification by a standard assay. Subsequently, RNAseq is performed on an Illumina MiSeq after the preparation of a sequencing library.
[0116] Examples 2 - NFAT Exemplary for activation GPCR Receptor screen
[0117] In this embodiment, Fig. 1a and 1b Potential compounds that induce GPCR signaling are screened using a transcription relay system containing nucleic acids as configured in [formula]. In the case of this embodiment, Fig. 1aThe nucleic acid contains the activation of the nuclear factor response element (NFAT) of activated T cells, which results in the expression of the synthetic transcription factor Gal4-VPR (containing the Gal4 DNA binding domain and the chimeric activation domain VP64-p65-Rta). Fig. 1b The nucleic acid contains a promoter that can be bound by the Gal4-VPR synthetic transcription factor and activated, which leads to the expression of reporter elements including the luciferase gene and the gene encoding UMI. The cells used are Fig. 1a and 1b It includes stably integrated nucleic acid(s) encoding the system and a given GPCR. Each UMI is associated with a given GPCR, allowing CRE expression to be mapped to a specific GPCR. This enables the assay to be multiplexed.
[0118] On Day 1, cells are plated in DMEM at a density of 35,000 cells / well in a 96-well assay plate. On Day 2, the medium is replaced with 0.5% FBS + DMEM. On Day 3, the medium is removed, and the test compound is added to 25 µl of Opti-mem at the desired concentration. After approximately 4 hours, the medium is removed and replaced with lysis buffer for RNA extraction. RNA is extracted using standard methods or kits, followed by quantification by standard assays. Subsequently, RNAseq is performed on an Illumina MiSeq after the preparation of a sequencing library.
[0119] Examples 3 - Multiple GPCRs CRE Exemplary for activation GPCR Receptor screen
[0120] In this embodiment, each do 1a and 1bPotential compounds that induce GPCR signaling are screened using more than 100 transcription relay systems containing nucleic acids as configured in [formula]. In the case of this embodiment, Fig. 1a Each nucleic acid contains cAMP response factor (CRE) activation that results in the expression of the synthetic transcription factor Gal4-VPR (including the Gal4 DNA binding domain and the chimeric activation domain VP64-p65-Rta). Fig. 1b Each nucleic acid contains a promoter that can be bound by the Gal4-VPR synthetic transcription factor and activated, which leads to the expression of reporter elements including the luciferase gene and the gene encoding UMI. The cell populations used are, respectively do 1a and 1b It includes stably integrated nucleic acid(s) encoding the system and a given single GPCR. Multiple cell populations of 100 or more, each encoding a single unique GPCR, are mixed together to form a mixed cell population. Each UMI is associated with a given GPCR, allowing CRE expression to be mapped to a specific GPCR. This enables the assay to be multiplexed.
[0121] On Day 1, the above-mentioned mixed cell population is plated in a 96-well assay plate at 35,000 cells / well in DMEM. On Day 2, the medium is replaced with 0.5% FBS + DMEM. On Day 3, the medium is removed, and the test compound is added to 25 µl of Opti-mem at the desired concentration. After approximately 4 hours, the medium is removed and replaced with lysis buffer for RNA extraction. RNA is extracted using a standard method or kit, and then quantified by a standard assay. Subsequently, RNAseq is performed on an Illumina MiSeq after the preparation of a sequencing library.
[0122] Examples 4 - Reporter Output Amplification Using Transfer Relays
[0123] The experiments in this example demonstrate an increase in luciferase signal and a decrease in the coefficient of variation of the luciferase signal when using a transcription relay system compared to a system without a transcription relay. HEK293-derived cells possessing a single integrated CRE-luciferase, or HEK293-derived cells possessing a single integrated UAS-luciferase along with multiple copies of semi-randomly integrated CRE-Gal4-VPR, were plated at 30,000 cells / well in 96-well plates coated with white walls and poly-L-lysine in 100 µl DMEM + 10% FBS. 50 µl Opti-mem containing 45 ng doxycycline was added to the cells. After 24 hours, DMSO was added. The cells were treated with DMSO for the specified period. After the specified incubation time, the medium was aspirated, replaced with 35 µl DMEM, and the cells were assayed using the Bright-Glo Luciferase Assay kit [Promega] according to the manufacturer's instructions. The resulting luciferase activity of cells possessing a single integrated CRE-luciferase (gray) and cells possessing a single integrated UAS-luciferase along with multiple copies of semi-randomly integrated CRE-Gal4-VPR (black) is presented in Figure 2. The experiment was technically performed in triples, and the coefficient of variation for each sample was calculated in Figure 3.
[0124] Examples 5 - Gal4 - VPR On the Degron Using tags
[0125] Inductive multiplication of the transmission relay
[0126] The experiments in this example demonstrate an induction-fold increase in luciferase signal when a degron tag is included on Gal4-VPR in a transcriptional relay system. HEK293-derived cells harboring a single integrated TRE-CHRM3::UAS-luciferase dual gene cassette and variously semi-randomly integrated FOS-Gal4-VPR-CP (with degron) or FOS-Gal4-VPR (without degron) were plated at 30,000 cells / well in white-walled poly-L-lysine-coated 96-well plates in 100 µl DMEM + 10% FBS. 50 µl Opti-mem containing 45 ng doxycycline was added to the cells. After 24 hours, the cells were treated with DMSO or 1 μM Carvacol for 8 hours. After the specified incubation time, the medium was aspirated, replaced with 35 µl of DMEM, and the cells were analyzed using the Bright-Glow Luciferase Assay Kit [Promega] according to the manufacturer's instructions. As a result, the ratio of luciferase activity in carvacol to luciferase activity in DMSO is plotted in Figure 4.
[0127] Examples 6 - NFAT Cell line containing reaction elements
[0128] The cell lines described in this embodiment have an integrated copy of the NFAT-responsive element transcription relay (an NFAT promoter that drives the transcription of synthetic transcription factors). These cell lines were generated as a pool of genetic heterogeneity with respect to copy number and integration site. From said pool, single-cell clones were isolated and expanded. These cell lines were further used to test their ability to detect multiple NFAT signaling by integrating GPCRs and UAS-luciferase-barcode reporters. From said 10 cell libraries, two were identified capable of detecting the highest number of distinct GPCR hits compared to control agonists: cb29 (composed of clone c713) and cb37 (composed of clone c708), as shown in Fig. 5.
[0129] Importantly, the isoclonal cell lines that generated these two cell libraries were found to share two common characteristics. First, these cell lines exhibited the highest amount of reporter expression under unstimulated conditions ( Fig. 6 , see "Basic activity - reverse transfection"). Second, and possibly in a dependent manner, the two corresponding cell libraries exhibited the lowest levels of variability ( Fig. 6 , see "BCV").
[0130] Although preferred embodiments of the present invention have been presented and described herein, it will be apparent to those skilled in the art that such embodiments are provided merely as examples. Now, those skilled in the art will conceive of numerous modifications, variations, and substitutions without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be used to practice the invention.
[0131] All publications, patent applications, registered patents, and other documents mentioned herein are incorporated by reference as each individual publication, patent application, registered patent, or other document is specifically and individually specified as being incorporated by reference in its entirety. Definitions contained in the incorporated text are excluded if they contradict the definitions in this disclosure.
Claims
Claim 1 A transcription relay system comprising: a) an exogenous transcription factor nucleic acid comprising a nucleotide sequence of a reaction factor regulatory promoter and a nucleotide sequence encoding a synthetic transcription factor, wherein the reaction factor regulatory promoter nucleotide sequence is located at the 5' end with respect to the nucleotide sequence encoding the synthetic transcription factor; and b) an exogenous reporter nucleic acid comprising a nucleotide sequence of a synthetic transcription factor promoter and a nucleotide sequence encoding a reporter, wherein the synthetic transcription factor promoter nucleotide sequence is located at the 5' end with respect to the nucleotide sequence encoding the reporter, and the synthetic transcription factor promoter nucleotide sequence can be bound by the synthetic transcription factor, and the reporter comprises a unique molecular identifier. Claim 2 A transcription relay system according to claim 1, wherein the reaction factor regulatory promoter nucleotide sequence comprises a cAMP reaction factor nucleotide sequence, an NFAT transcription factor reaction factor nucleotide sequence, an FOS promoter nucleotide sequence, or a serum reaction factor nucleotide sequence. Claim 3 A transcription relay system according to claim 1 or 2, wherein the synthetic transcription factor comprises a DNA binding domain and a transcription activation domain, and the DNA binding domain and the transcription activation domain are from different transcription factors. Claim 4 In paragraph 3, the DNA binding domain is a transcription relay system from Gal4, PPR1, Lac9, or LexA. Claim 5 A transcription relay system according to claim 4, wherein the DNA binding domain comprises an amino acid sequence identical to the amino acid sequence described in SEQ ID NO.
1. Claim 6 A transmission relay system according to paragraph 3, wherein the transmission activation domain comprises VP64, p65, and Rta. Claim 7 A transcription relay system according to claim 6, wherein the transcription activation domain comprises the same amino acid sequence as the amino acid sequence described in SEQ ID NO.
14. Claim 8 A transcription relay system according to claim 1 or 2, wherein the synthetic transcription factor comprises a polypeptide sequence that destabilizes the synthetic transcription factor, and the polypeptide sequence comprises a PEST or CL1 polypeptide sequence. Claim 9 A transcription relay system according to claim 1 or 2, wherein the synthetic transcription factor promoter nucleotide sequence comprises a nucleotide sequence that can be combined by Gal4, PPR1, Lac9, or LexA. Claim 10 A transcription relay system according to claim 1 or 2, wherein the reporter comprises a fluorescent protein, a luciferase protein, a beta-galactosidase, a beta-glucuronidase, a chloramphenicol acetyltransferase, or a secreted placental alkaline phosphatase. Claim 11 A transcription relay system according to claim 1 or 2, wherein the unique molecular identifier is unique to the test polypeptide. Claim 12 A transcription relay system according to claim 1 or 2, wherein the exogenous transcription factor nucleic acid comprises a nucleotide sequence adjacent to the reaction element regulatory promoter nucleotide sequence that can be bound by a transcription repressor. Claim 13 A transcription relay system according to claim 12, wherein the exogenous transcription factor nucleic acid comprises a nucleotide sequence adjacent to the reaction factor regulatory promoter nucleotide sequence that extends the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor. Claim 14 A transcription relay system according to claim 13, wherein the 5' untranslated region of the mRNA encoded by the nucleotide sequence encoding the synthetic transcription factor comprises one or more sequences that reduce the translation of the synthetic transcription factor. Claim 15 delete Claim 16 delete Claim 17 delete Claim 18 delete Claim 19 delete Claim 20 delete Claim 21 delete Claim 22 delete Claim 23 delete Claim 24 delete Claim 25 delete Claim 26 delete Claim 27 delete Claim 28 delete Claim 29 delete Claim 30 delete Claim 31 delete Claim 32 delete Claim 33 delete Claim 34 delete Claim 35 delete Claim 36 delete Claim 37 delete Claim 38 delete Claim 39 delete Claim 40 delete
